Lepirudin is a safe and effective anticoagulant for patients with heparin-associated antiplatelet antibodies
- 1 July 2001
- journal article
- Published by Elsevier in Journal of Vascular Surgery
- Vol. 34 (1) , 17-20
- https://doi.org/10.1067/mva.2001.115602
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Clinical correlates and course of thrombocytopenia during percutaneous coronary intervention in the era of abciximab platelet glycoprotein IIb/IIIa blockadeAmerican Heart Journal, 2000
- Lepirudin (Recombinant Hirudin) for Parenteral Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Immunologic response to recombinant hirudin in HIT type II patients during long‐term treatmentBritish Journal of Haematology, 1999
- The role of heparin-associated antiplatelet antibodies in the outcome of arterial reconstructionJournal of Vascular Surgery, 1999
- Recombinant Hirudin (Lepirudin) Provides Safe and Effective Anticoagulation in Patients With Heparin-Induced ThrombocytopeniaCirculation, 1999
- Reduced morbidity and mortality rates of the heparin-induced thrombocytopenia syndromeJournal of Vascular Surgery, 1998
- The glycoprotein IIb/IIIa antagonist c7E3 inhibits platelet aggregation in the presence of heparin-associated antibodiesJournal of Vascular Surgery, 1997
- Use of enoxaparin in patients with heparin-induced thrombocytopenia syndromeJournal of Vascular Surgery, 1996
- Reexposure to heparin of patients with heparin-associated antibodiesJournal of Vascular Surgery, 1989
- Heparin-lnduced Thrombocytopenia, Thrombosis, and HemorrhageAnnals of Surgery, 1983